Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection
暂无分享,去创建一个
L. Medeiros | Shaoying Li | J. Jorgensen | Sa A. Wang | Fuli Jia | S. Loghavi | B. Thakral | Shimin Hu | Jie Xu | C. Ok | Wei Wang | Jeffrey L. Jorgensen | Sa A. Wang | L. J. Medeiros
[1] J. Philippé,et al. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party , 2021, HemaSphere.
[2] K. Döhner,et al. 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.
[3] M. Konopleva,et al. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia , 2021, British journal of haematology.
[4] M. Konopleva,et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. , 2020, Blood advances.
[5] M. Konopleva,et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. , 2020, Blood advances.
[6] G. Stefanzl,et al. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. , 2020, Blood advances.
[7] Virginia Litwin,et al. High‐sensitivity flow cytometric assays: Considerations for design control and analytical validation for identification of Rare events , 2020, Cytometry. Part B, Clinical cytometry.
[8] Yow-Ming C Wang,et al. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, B , 2019, Bioanalysis.
[9] M. Konopleva,et al. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation , 2019, American journal of hematology.
[10] W. Wong,et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. , 2019, Blood advances.
[11] K. Rezvani,et al. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] F. Ravandi,et al. Evaluating measurable residual disease in acute myeloid leukemia. , 2018, Blood advances.
[13] J. Downing,et al. Universal monitoring of minimal residual disease in acute myeloid leukemia. , 2018, JCI insight.
[14] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[15] J. Jorgensen,et al. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.
[16] D. Marin,et al. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] M. Konopleva,et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia , 2017, Cancer.
[18] F. Ravandi,et al. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. , 2016, American journal of clinical pathology.
[19] M. Routbort,et al. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia , 2015, American journal of hematology.
[20] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[21] J. Jorgensen,et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future , 2014, Bone Marrow Transplantation.
[22] Ming Yan,et al. Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteria , 2013, Cytometry. Part B, Clinical cytometry.
[23] Yu Wang,et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. , 2013, Blood.
[24] F. Sigaux,et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Shpall,et al. A Novel Disease Risk Model for Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] H. Kantarjian,et al. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse , 2018, Leukemia.